Melanotan II at a Glance

• Melanotan II is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, developed in the 1980s and 1990s at the University of Arizona.
• Its defining pharmacological property is non-selectivity. It is a potent agonist at MC1R, MC3R, MC4R and MC5R and that promiscuity, not any single receptor interaction, is the central fact governing both its biology and its adverse-event profile.
• MC1R agonism drives melanogenesis in cutaneous melanocytes. Central MC4R agonism produces effects on appetite, autonomic tone and sexual function, and it was that central activity that led to a separate development programme for bremelanotide (PT-141) the C-terminal free-acid relative that reached approval.
• The published adverse-event literature is substantial and is the most important part of the file: nausea, flushing and spontaneous erections in the original phase-I work, and a subsequent case-report literature encompassing eruptive and changing melanocytic naevi, melanoma, rhabdomyolysis with systemic toxicity, posterior reversible encephalopathy syndrome and renal infarction. Analytical work on unregulated, online-available α-MSH analogue products has also been published, and product identity and content in that market cannot be assumed.
• Melanotan II is not approved by any medicines regulator anywhere. The UK MHRA and other national agencies have issued public warnings against its sale, and it is research-use-only material with no approved labelling, specification or route of administration.

What Is Melanotan II?

Melanotan II is a seven-residue synthetic peptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. It is catalogued in PubChem as Melanotan II, CID 92432, with molecular formula C₅₀H₆₉N₁₅O₉ and a molecular weight of approximately 1,024 Da for the free base. Commercial research material is usually supplied as an acetate salt.

Four structural decisions define it.

It is cyclic. A lactam bridge links the aspartate side-chain carboxyl to the lysine side-chain amine. Native α-MSH is linear, with a short plasma half-life and considerable conformational freedom; cyclisation locks the pharmacophore into a receptor-competent conformation and removes most of the backbone accessibility proteases exploit, giving far greater potency and metabolic stability.

It is truncated. The message sequence of α-MSH is the core tetrapeptide His-Phe-Arg-Trp; everything outside it contributes affinity and selectivity rather than intrinsic activity. Melanotan II retains that core and discards most of the rest.

It carries two unnatural substitutions. Nle (norleucine) replaces the methionine at position four, removing the most oxidation-prone residue in the sequence. D-Phe replaces L-phenylalanine at position seven, a substitution first shown in the linear analogue Nle⁴-D-Phe⁷-α-MSH to produce a large increase in potency and duration.

The C-terminus is amidated. This is the single feature separating melanotan II from bremelanotide, otherwise the same macrocycle terminating in a free carboxylic acid, one change that alters the receptor-activity profile and is why the two have different development histories.

How Does Melanotan II Work?

The Melanocortin System

The melanocortins are cleaved from a single precursor, pro-opiomelanocortin (POMC): α-MSH, β-MSH, γ-MSH and ACTH. They act on five class A G-protein-coupled receptors, MC1R through MC5R all signalling principally through Gs, adenylate cyclase and cAMP/PKA. The system is unusual in having endogenous antagonists as well as agonists, agouti-signalling protein at MC1R, agouti-related peptide at MC3R and MC4R, so melanocortin tone reflects a balance rather than a ligand concentration. The five receptors are anatomically and functionally distinct:

MC2R is the exception that matters. It responds only to ACTH, because activation requires a basic motif present in ACTH and absent from α-MSH. Melanotan II therefore does not act at MC2R and has no direct adrenal steroidogenic action, the one melanocortin receptor it leaves alone.

MC1R and Melanogenesis

MC1R is expressed on epidermal melanocytes. Agonist binding raises intracellular cAMP, activates PKA and phosphorylates CREB, which drives transcription of MITF the master regulator of the melanocyte lineage. MITF in turn upregulates tyrosinase TRP-1 and TRP-2, the enzymatic machinery of melanin synthesis, and shifts production from red-yellow pheomelanin toward brown-black eumelanin.

This is the pathway ultraviolet radiation normally engages indirectly: UV-induced DNA damage in keratinocytes drives p53-dependent POMC transcription, local α-MSH release and paracrine MC1R signalling on neighbouring melanocytes. A systemic MC1R agonist engages the same receptor without the upstream DNA damage, which is the mechanistic basis of the melanotropic peptide field.

Loss-of-function MC1R variants in humans produce the red-hair, fair-skin, poor-tanning phenotype and are an established melanoma risk factor. That relationship is why MC1R attracted pharmacological interest, and also why the melanoma case reports discussed below are taken seriously rather than dismissed: MC1R sits directly on the biology of the cell of origin.

MC4R, MC3R and Central Melanocortin Signalling

MC4R is expressed in the hypothalamic paraventricular nucleus, the brainstem and the spinal cord, and is the principal central effector of the leptin–POMC–melanocortin pathway for energy balance; heterozygous loss-of-function MC4R mutations are the commonest known monogenic cause of human obesity. The receptor also modulates autonomic outflow including sympathetic tone and blood pressure, and participates in central control of sexual function. MC3R is co-expressed with MC4R in several hypothalamic regions and contributes to energy homeostasis, autonomic regulation and the resolution phase of inflammation.

Melanotan II is a potent agonist at both, and this is the point at which it stops being a dermatological agent: a molecule that reaches the central nervous system and activates MC3R and MC4R is a neuroendocrine and autonomic drug and its adverse-event profile follows from that far more than from anything happening in the skin.

MC5R and the Consequences of Non-Selectivity

MC5R is expressed on exocrine tissue, sebaceous, lacrimal and other glands, and on lymphocytes. Melanotan II activates it along with everything else.

The central pharmacological point can be stated in one sentence: melanotan II has no meaningful receptor selectivity across MC1R, MC3R, MC4R and MC5R so any administration engages cutaneous pigmentation, central appetite and autonomic circuits, sexual-function pathways, exocrine secretion and immune signalling simultaneously. There is no dose at which it is a selective MC1R agonist.

A compound with four active targets across four organ systems produces effects in all four, and a reader assessing the adverse-event literature should expect exactly the heterogeneous, multi-system pattern it shows. Selectivity is the design problem the field spent two decades solving, and the two melanocortin drugs that reached approval are the products of that effort.

Research Evidence

Origin: The University of Arizona Programme

Melanotan II came out of the melanotropin work of Victor Hruby, Mac Hadley and colleagues at the University of Arizona, a structure–activity programme on α-MSH that produced both compounds the field now calls “melanotan”. The linear analogue Nle⁴-D-Phe⁷-α-MSH became afamelanotide (melanotan-I); the cyclic, truncated analogue became melanotan II.

The clinical record for the parent compound consists chiefly of one small early-phase study. Dorr and colleagues (1996, PMID 8637402) reported a pilot phase-I evaluation of melanotan-II, described as a superpotent cyclic melanotropic peptide, administered subcutaneously to a small number of male subjects. Two classes of finding emerged and both have defined the compound ever since: increased cutaneous pigmentation, confirming MC1R activity in humans; and adverse events, nausea, facial flushing, stretching and yawning, and spontaneous penile erections that were central melanocortin effects rather than dermatological ones. An unanticipated, reproducible effect on sexual function in an early-phase dermatological study is precisely the kind of finding that generates a separate drug programme, and it did.

Pigmentation Studies

The dermatological literature on melanotropic peptides was reviewed for a clinical audience by Langan (2010, PMID 20545686) in the British Journal of Dermatology, under a title, Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’?, that captures the field’s difficulty: legitimate MC1R pharmacology developing in parallel with a large unregulated market, the two persistently confused in the secondary literature.

The pigmentation findings are not in dispute; MC1R agonism increases melanin synthesis in human skin. What has never been established for melanotan II is any favourable benefit–risk relationship in a controlled setting, because no adequately powered controlled trial of it for any pigmentary indication has been completed. The MC1R hypothesis was carried forward by the selective compound, not by this one.

The Central Effects and the Bremelanotide Programme

The effects on sexual function observed in early melanotan II work were traced to central MC3R/MC4R signalling rather than any peripheral vascular action, and that mechanism became the basis of a distinct development programme built around bremelanotide (PT-141) the C-terminal free-acid analogue of melanotan II.

Bremelanotide was approved by the FDA in 2019 as Vyleesi a melanocortin receptor agonist indicated for the treatment of acquired, generalised hypoactive sexual desire disorder in premenopausal women (FDA prescribing information, NDA 210557). Its labelling documents nausea and flushing as common adverse reactions and carries warnings relating to transient blood-pressure increase and to focal hyperpigmentation, the same three effects, arising from the same receptor promiscuity, in a compound that went through formal development.

That comparison is the most useful single fact for a clinical reader: the adverse effects attributed to melanotan II are not artefacts of an unregulated market but on-target melanocortin pharmacology documented in a regulated product’s approved labelling.

The Documented Adverse-Event Literature

This is the substantial part of the melanotan II record, and it should be reported plainly.

Eruptive and changing melanocytic naevi. Cardones and Grichnik (2009, PMID 19380666) described α-melanocyte-stimulating hormone-induced eruptive naevi, new naevi and darkening of existing lesions in association with melanotan use. The same phenomenon was reported in the UK in 2009 in association with unlicensed “sun tan jab” products (PMID 19174439) and in the first Swedish cases (PMID 23451671). Beyond the lesions themselves, the clinically important consequence is diagnostic interference: darkening and proliferation of pigmented lesions degrades the clinical and dermoscopic signals used for melanoma surveillance.

Melanoma. Multiple independent case reports associate melanotan exposure with melanoma (PMID 21564053, PMID 24355990). Case reports cannot establish causation, and no cohort or case-control study exists that could. The honest framing is a plausible mechanism acting on the melanocyte lineage, an established set of case reports, no epidemiological confirmation, and no study capable of excluding a risk either.

Rhabdomyolysis and systemic toxicity. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis has been reported in the toxicology literature (PMID 23121206), a presentation with no obvious melanocortin explanation and one that raises the question of product contamination alongside pharmacology.

Posterior reversible encephalopathy syndrome. A case of melanotan-associated PRES was reported in Annals of Internal Medicine (PMID 23648958). PRES is typically associated with acute blood-pressure dysregulation and endothelial injury, and a compound with documented central autonomic and pressor effects is a mechanistically coherent, if unproven, candidate.

Vascular events. Renal infarction has been reported in association with melanotan II in a case report with accompanying literature review published in CEN Case Reports (2020). Taken with the PRES case and the pressor signal in bremelanotide’s approved labelling, the vascular and autonomic thread running through this literature is the one a physician reader should weight most heavily.

For a neurological and psychiatric readership the summary is uncomfortable but straightforward: a non-selective melanocortin agonist reaching the CNS has produced published reports of a cerebrovascular syndrome, a vascular occlusive event and a systemic toxicity syndrome, alongside a dermatological signal involving the cell of origin of melanoma. No other compound commonly listed in research peptide catalogues carries a documented safety signal of this breadth.

Product Composition in the Unregulated Market

A separate line of evidence concerns what unregulated products actually contain. An observational study of unregulated, online-available synthetic α-MSH analogue products was published in the Journal of the American Academy of Dermatology (2021, PMID 34333078).

The analytical point generalises beyond that single study. Where a compound is not manufactured to any regulated standard, adverse events reported in association with it cannot be confidently attributed to the named molecule, because identity, purity and content are unverified. That cuts both ways: some reported toxicity may reflect impurities rather than melanocortin pharmacology, and the pharmacology of the actual administered material is unknown.

What Remains Unknown

Whether the melanoma association is causal. No cohort study, case-control study or registry analysis exists. The mechanism is plausible and the case reports are real, but the epidemiology has not been done and probably cannot be done in an unregulated population.

Human pharmacokinetics. Absorption, distribution, CNS penetration, metabolism and elimination in humans are not characterised in the public literature, so no exposure–response relationship can be constructed for any effect, adverse or otherwise.

Long-term consequences of chronic MC3R/MC4R agonism. Nothing in the published record addresses what repeated exposure does to energy balance, autonomic tone or blood pressure over months or years.

Comparison: Melanotan II, Bremelanotide and Afamelanotide

Three molecules from the same structure–activity programme illustrate what selectivity is worth.

Afamelanotide was approved as Scenesse in October 2019 (FDA approval letter, NDA 210797) for erythropoietic protoporphyria, a narrow indication in which increased eumelanin has a defined clinical purpose and a benefit–risk assessment could actually be made.

The pattern is instructive. The two molecules that reached approval each did so by being directed at one arm of the system and taken through controlled trials that generated a characterised safety profile. Melanotan II, which engages all four active receptors at once, has neither. Catalogues that list PT-141 alongside melanotan II are listing two compounds whose regulatory and evidentiary positions are not comparable, and research-grade PT-141 is not the approved product either.

Handling and Reconstitution of a Cyclic Heptapeptide

At roughly 1,024 Da with a macrocyclic constraint, melanotan II is chemically more robust than a long linear peptide and less robust than its small size suggests. Three properties shape handling.

The lactam bridge is a stability asset and a liability. Cyclisation removes backbone flexibility and confers substantial resistance to exopeptidases, which is why lyophilised material is stable held cold and dry. But hydrolytic ring-opening in solution yields a linear peptide that is a different pharmacological entity, the degradation product that matters most, and the one least likely to be detected by a purity method that only integrates a main peak.

Tryptophan is the oxidation-prone residue. The norleucine substitution removed the methionine, but the tryptophan remains and is susceptible to photo-oxidation and metal-catalysed oxidation. Light protection is not a formality here: amber vials, foil overwrap or dark storage are appropriate, and oxidised tryptophan species are a realistic impurity in poorly handled material.

It adsorbs to surfaces. The arginine and lysine give a cationic peptide that binds readily to glass and untreated polypropylene at dilute concentrations, so low-binding labware is worth using in quantitative work.

Reconstitution follows the standard sequence. Allow the vial to reach room temperature before opening so condensation does not form on a cold cake; disinfect the septum with 70% isopropyl alcohol and let it dry; introduce the diluent slowly, down the inner wall of the vial rather than jetting it onto the cake, since a stream striking the cake creates local shear and a large air–liquid interface. Swirl or roll gently; never shake.

Where a vial is entered repeatedly, a preserved monographed diluent is the conventional choice, and the bacteriostatic water listed alongside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most protocols specify. Two caveats belong in the record: the benzyl alcohol preservative is not inert toward peptides, so a single-entry analytical preparation is better served by unpreserved sterile water; and Bacteriostatic Water for Injection is contraindicated in neonatal use because of benzyl alcohol toxicity.

Store reconstituted solution at 2–8 °C, rigorously protected from light, and aliquot at the point of reconstitution rather than freeze-thawing a single vial repeatedly. Record the concentration in mg/mL rather than the volume added, and log the diluent lot alongside the peptide lot.

Is Melanotan II Approved Anywhere?

No. Melanotan II holds no marketing authorisation in any jurisdiction for any indication, in any formulation. It has never completed a controlled trial adequate to support one, and it is not in active regulated development.

The regulatory position is more active than simple absence of approval. Melanotan products have been the subject of public warnings by national medicines regulators: the United Kingdom’s Medicines and Healthcare products Regulatory Agency has repeatedly stated that melanotan is an unlicensed medicine, that its sale is illegal and that it should not be used, a position restated across more than a decade, alongside similar statements from agencies in Ireland, Scandinavia and Australia. UK regulatory concern in 2009 was reported in the medical press specifically in connection with changes in melanocytic naevi (PMID 19174439).

The existence of two approved melanocortin products confers no status on melanotan II. Vyleesi contains bremelanotide; Scenesse contains afamelanotide. Neither contains melanotan II. A research vial has no marketing authorisation, no approved labelling, no regulated manufacturing standard, no sterility or endotoxin specification and no approved route of administration.

Laboratories in sport-science settings should note separately that melanocortin receptor agonists and related unapproved peptide agents fall within categories addressed by anti-doping regulation, and should consult the current World Anti-Doping Agency Prohibited List directly.

Where Research-Grade Melanotan II Is Sourced

Because nothing regulatory underwrites laboratory material, documentation is the only evidence a laboratory has. A defensible purchase record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than a representative batch.
• Third-party HPLC purity data with a named laboratory and a test date. For a cyclic peptide the impurities that matter are the ring-opened linear form oxidised tryptophan species, and deletion sequences, and a method that resolves none of these will still report a high purity figure.
• Mass spectrometry confirming identity with an observed mass consistent with the expected ~1,024 Da free base. The cyclic and ring-opened forms differ by 18 Da, so mass spectrometry distinguishes them where a chromatogram may not, and the free-acid analogue differs from the amide by 1 Da.
• Declared net peptide content distinct from gross vial fill weight, since acetate counterion and residual water account for a substantial fraction of the mass.
• Cold-chain shipping and light-protective packaging given the tryptophan, and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags are mostly absences and overreaches. A certificate with no laboratory name, test date or lot reference is decoration rather than evidence, and a supplier who will not produce documentation for the lot in hand has answered the question. For this compound specifically, any listing that presents cosmetic framing, before-and-after imagery, a use protocol or a suggested schedule has abandoned the research-use-only frame entirely, and given the documented adverse-event literature, that is a compliance failure rather than a marketing flourish. A catalogue that lists melanotan 2 as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis, identity confirmed by mass spectrometry, declared net peptide content, light-protected cold-chain handling, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

What receptors does melanotan II act on?

It is a potent agonist at MC1R, MC3R, MC4R and MC5R. It does not activate MC2R, the ACTH receptor, because MC2R activation requires a basic motif present in ACTH and absent from α-MSH analogues. The absence of selectivity across the other four receptors is the compound’s defining pharmacological characteristic and the origin of its multi-system effect profile.

How does melanotan II differ from melanotan I?

They are different molecules from the same programme. Melanotan-I is afamelanotide a linear 13-residue α-MSH analogue directed at MC1R, approved as Scenesse for erythropoietic protoporphyria. Melanotan II is a cyclic, truncated heptapeptide, non-selective across MC1R, MC3R, MC4R and MC5R, never approved anywhere. They are not interchangeable in any context.

What is the relationship between melanotan II and PT-141?

Bremelanotide (PT-141) is the C-terminal free-acid analogue of melanotan II, the same macrocycle terminating in a carboxylic acid rather than an amide. It was developed after central effects were observed in early melanotan II work and was approved by the FDA in 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 is not that approved product.

What adverse effects are documented in the literature?

The original phase-I report described nausea, facial flushing, stretching and yawning, and spontaneous erections. The subsequent case-report literature documents eruptive and changing melanocytic naevi, melanoma, rhabdomyolysis with systemic toxicity, posterior reversible encephalopathy syndrome and renal infarction. Nausea, flushing, transient blood-pressure increase and focal hyperpigmentation also appear in the approved labelling of the related compound bremelanotide, indicating that several are on-target melanocortin effects rather than contamination artefacts.

Does melanotan II cause melanoma?

This is not established, and the available evidence cannot establish it either way. There are multiple independent published case reports of melanoma in association with melanotan exposure, and there is a coherent biological mechanism, since MC1R signalling acts directly on the melanocyte lineage. There is no cohort study, case-control study or registry analysis. Case reports demonstrate association in individuals, not causation in populations, and the absence of epidemiology is not evidence of safety.

Why is the naevus literature clinically important beyond the lesions themselves?

Because it degrades melanoma surveillance. Darkening of existing naevi and the appearance of new ones alter exactly the clinical and dermoscopic features used to identify early melanoma, which makes assessment harder at the same time as the population being assessed has a documented case-report association with melanoma. That interaction, rather than the cosmetic appearance of the lesions, is the reason the dermatology literature treats the finding seriously.

The Bottom Line

Melanotan II is pharmacologically interesting and, on the published record, the least reassuring compound commonly listed in research peptide catalogues. Both follow from the same property.

The interest is real. It is a well-designed molecule, a cyclised, truncated, stabilised α-MSH analogue that demonstrated in humans, in 1996, that systemic melanocortin agonism reaches both cutaneous and central targets, and the compound in which the central effects that generated the bremelanotide programme were first observed.

The problem is that the same non-selectivity that makes it an interesting probe makes it an unacceptable therapeutic candidate and the field understood this quickly. MC1R, MC3R, MC4R and MC5R are engaged together, across skin, hypothalamus, brainstem, spinal cord, exocrine glands and lymphocytes. There is no dose that isolates one of them.

The adverse-event literature reads as that pharmacology predicts, with additions it does not. Nausea, flushing and spontaneous erections in the original phase-I work are on-target central melanocortin effects, and the first two appear in bremelanotide’s approved labelling. Eruptive and changing melanocytic naevi are on-target MC1R effects with a real clinical cost, because they interfere with the surveillance used to detect melanoma early. Then the reports mechanism alone does not account for: melanoma, rhabdomyolysis with systemic toxicity, posterior reversible encephalopathy syndrome, renal infarction. None is established as causal. All are published. None has been excluded, and no study capable of excluding them has been done.

Set against that, two selective descendants went through controlled development and were approved in 2019, one MC1R-directed, one MC4R-directed, each with a characterised safety profile and a defined indication. That is what the melanocortin system yielded when approached selectively. Melanotan II is what it yielded when it was not, and the difference is the whole argument for selectivity in receptor pharmacology.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Melanotan II and all other compounds discussed in this article are intended for laboratory research use only. Melanotan II is not an approved drug product in any jurisdiction: no marketing authorisation, no approved labelling, no regulated manufacturing or sterility standard, no approved route of administration and no approved indication. National medicines regulators, including the UK MHRA, have issued public warnings against its sale and use.

Nothing here is medical, veterinary or pharmaceutical advice, and nothing constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Research peptides described here are not for human or veterinary use. This article does not describe how to use melanotan II and deliberately contains no administration guidance of any kind.

Descriptions of adverse events summarise published case reports and clinical literature; case reports establish association in individuals, not causation in populations, and the absence of epidemiological confirmation is not evidence of safety. Descriptions of approved products, including Vyleesi (bremelanotide) and Scenesse (afamelanotide), summarise the regulatory record and confer no status on research-grade material. Any reader with concerns about a changing pigmented skin lesion should consult a qualified healthcare professional without delay.

Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Related posts:

Visualization in the Pediatric Patient Nerve Monitoring Factors in a Standard Work Protocol for Adult Deformity Surgery Medical Complications Peptides for Anxiety: Research, Potential Mechanisms, and What to Know

Stay updated, free articles. Join our Telegram channel

Join